Pre-Market Update: CMMB - Breakout on NewsOverview
Looking for an incoming buy-in opportunity on APO - Apollo around the $158-$160 range by mid-February. This setup aligns with a potential longer-term hold and a continuation back to its previous all-time highs (ATHs). If it follows an incremental climb higher, this could yield a 19-20%+ gain, with even more potential if it surpasses those ATHs. The technical and fundamental setup is looking highly favorable.
Technical Analysis:
Trend and Breakout Potential:
APO is currently attempting to break out of a descending trendline (red line) following its recent pullback. The price action suggests the $158–$160 zone will act as strong support, which also aligns with the broader upward green trendline visible in the chart.
Moving Averages as Support:
The price action is converging near key moving averages, which could act as dynamic support zones. A potential bounce from this region is supported by historical performance around these levels.
Volume Analysis:
Recent volume spikes around critical price zones indicate heightened institutional interest, reinforcing the potential for a reversal or sustained breakout.
Fibonacci Levels:
The $158-$160 range also aligns with the 61.8% Fibonacci retracement level, a critical zone watched by institutional traders. This provides an added layer of confidence in the identified support.
Risk/Reward Setup
With a potential entry around $158, targeting the ATH of $193 provides a compelling risk-to-reward ratio. A stop-loss placed around $150 ensures the risk is well-managed, with an estimated R:R exceeding 2:1.
Fundamental Analysis
Apollo Global Management’s solid fundamentals further support the case for a long-term hold:
Fundamental Analysis
Apollo Global Management’s strong fundamentals reinforce the case for a long-term hold:
Earnings Per Share (EPS): $8.28 (trailing twelve months), reflecting a YoY growth of 141.45%, showcasing the company’s robust profitability rebound.
Dividends Per Share: $1.72 (TTM), with a YoY growth of 6.98%, indicating steady shareholder returns and dividend stability.
Strong Historical Growth: Apollo has demonstrated significant earnings resilience, recovering from a loss in 2022 (-$3.43) to positive EPS in 2023 ($8.28).
Sector Outlook: As a leading asset management firm, Apollo is well-positioned to benefit from market trends favoring alternative investments, which are expected to grow substantially over the coming years.
Upcoming Catalysts
Keep an eye on any earnings reports or significant corporate announcements that could act as catalysts for the next leg higher. These events may also validate the technical setup and the expected rebound.
Conclusion
APO is setting up for a strong rebound from the $158–$160 level, with technical, volume, and fundamental indicators all pointing towards a bullish continuation. The upside potential back to the ATH of $193 represents a significant gain, making this a great opportunity for a longer-term hold. The setup is looking excellent for patient investors.
CMMB
CMMBChemomab Therapeutics Ltd (NASDAQ:CMMB) My opinion remains intact about this small bio cap. I will not sell a single share below $40 unless something bad happens, but that does not seem to be the case according to the recent news and reports. The stock has been falling on very low volume. The company has a great pipeline and the existing cash position is expected to fund the Company's current operating plan until mid 2023. The stock market is a device for transferring money from the impatient to the patient" Warren Buffet. I remember being called a pumper on PLUG or MARA when the stocks were trading at $2. NOTE: The 2 Wall Street analysts offering 12-month price forecasts for Chemomab Therapeutics Ltd have a median target of 43.50, with a high estimate of 45.00 and a low estimate of 42.00
CMMBChemomab Therapeutics Ltd (NASDAQ:CMMB) My long position on this small bio play remains intact. On the technical side, the stock has been pulling back on low volume to test the breakout zone around the $20 area. If this zone is respected next week, I expect that the next rebound will push the price up to $27. Money flow has been very solid over the past days and the accumulation/distribution continues to be bullish, we just might be on our way to higher prices. NOTE: The company has a poster presentation scheduled for Wednesday at the International Liver Congress 2021 (EASL). Analysts' price target range consensus $43
CMMBI think Chemomab Therapeutics Ltd (NASDAQ:CMMB) is building a nice base for take off. Some technical indicators are showing positive divergences on a daily basis. We could be in the early stages of a nice rally for this stock. Keep a close eye on it going forward. The stock currently trades at just over $18 a share, but analysts have targets pegged as high as $45 a share, suggesting as much as 120% upside.
Short Squeeze - CMMBIdea for Chemomab Therapeutics Ltd.:
- 131% borrow fee for shares. 47 shares available for borrow, according to iborrowdesk.
- Bottom of Risk Range:
- S3 Filing Sales Agreement with Cantor Fitzgerald & Co. dated Apr 30, 2021. fintel.io
- Cantor Fitzgerald assigned overweight rating on CMMB and raised price target to $45. www.marketbeat.com
- Good short squeeze material.
- Non Optionable.
Bought the shares $16.69
Expect share dilution $40-$50
GLHF
- DPT
CMMBI've mentioned Chemomab Therapeutics Ltd (NASDAQ:CMMB) for the bulls out there. On Friday, Oppenheimer initiated coverage on the stock with an Outperform rating and announced a price target of $42 per share. It seems that analysts are also seeing what I'm seeing, a stock trading at bargain prices with a tremendous potential going forward and a very low float. From a technical standpoint, the stock has built a good support around $19.2 and $20 recently and does have the chance to go up. Any breakout above the $25 level next week would be a positive sign.